期刊文献+

链霉蛋白酶对幽门螺杆菌感染患者胃癌组织MUC1及MUC5AC的影响 被引量:4

Effect of pronase on MUC1 and MUC5AC of gastric cancer patients with Helicobacter pylori infection
下载PDF
导出
摘要 目的探讨链霉蛋白酶对幽门螺杆菌(Helicobacter pylori,H.pylori)感染患者的胃癌组织MUC1及MUC5AC的影响。方法取诊断为胃癌且呼气试验阳性患者的术后标本,置于生理盐水、链霉蛋白酶及乙酰半胱氨酸中浸泡30 min,经免疫组化染色后制成切片,观察MUC1及MUC5AC的表达,并判定结果。结果经过链霉蛋白酶及乙酰半胱氨酸处理过的MUC1及MUC5AC水平降低,链霉蛋白酶组MUC1较生理盐水组MUC1比例增加,且两组MUC1/MUC5AC比例增加。结论链霉蛋白酶可以降低H.pylori感染的胃癌患者MUC1和MUC5AC的水平,链霉蛋白酶可以破坏H.pylori赖以生存的胃黏液凝胶层水平。经过链霉蛋白酶处理后,黏液层抗H.pylori的能力可能会增强。这为根除H.pylori提供了一种新的思路。 Objective To investigate the effect of pronase on MUC1 and MUC5AC of gastric cancer patients with Helicobacter pylori(H.pylori) infection.Methods The specimens of the patients with positive gastric cancer and positive breath test were soaked in saline,pronase and acetylcysteine for 30 minutes,and the expressions of MUC1 and MUC5AC were observed and the results were determined.Results The levels of MUC1 and MUC5AC treated by pronase and acetylcysteine were decreased,and the proportion of MUC1 in the pronase group was increased compared with the MUC1 in the saline group,and the proportion of MUC1/MUC5AC was increased in the two groups.Conclusion Pronase can reduce the levels of MUC1 and MUC5AC in patients with H.pylori infection,and pronase can destroy the level of gastric mucous gel layer on which H.pylori is dependent.After being treated with streptomyces,the ability of mucus layer to fight H.pylori is likely to increase.All these provide a new way to eradicate H.pylori.
作者 董浩 金世禄 张建 DONG Hao;JIN Shilu;ZHANG Jian(School of Clinical Medicine,Binzhou Medical University,Yantai 264003;Department of Gastroenterology;Department of Pathology,Binzhou People's Hospital Affiliated to Binzhou Medical University,China)
出处 《胃肠病学和肝病学杂志》 CAS 2018年第12期1403-1406,共4页 Chinese Journal of Gastroenterology and Hepatology
关键词 链霉蛋白酶 黏蛋白 幽门螺杆菌 Pronase Mucin Helicobacter pylori
  • 相关文献

参考文献4

二级参考文献53

  • 1Floriana Giorgio,Mariabeatrice Principi,Vincenzo De Francesco,Angelo Zullo,Giuseppe Losurdo,Alfredo Di Leo,Enzo Ierardi.主要 clarithromycin 抵抗到 Helicobacter pylori : 这是为三倍的治疗失败的主要原因?[J].World Journal of Gastrointestinal Pathophysiology,2013,4(3):43-46. 被引量:10
  • 2Vincenzo De Francesco,Enzo Ierardi,Cesare Hassan,Angelo Zullo.Helicobacter pylori therapy:Present and future[J].World Journal of Gastrointestinal Pharmacology and Therapeutics,2012,3(4):68-73. 被引量:7
  • 3徐智民,潘俊辉,宋卫生,孙勇,赖卓胜,王亚东,张万岱.幽门螺杆菌尿素酶金标抗体检查法与^(14)C-尿素呼气试验检测幽门螺杆菌感染的对照研究[J].现代消化及介入诊疗,2003,8(3):156-157. 被引量:2
  • 4李瑜元 胡品津 见:胡伏莲 周殿元 主编.幽门螺杆菌的流行病学[A].见:胡伏莲,周殿元,主编.幽门螺杆菌感染的基础与临床(修订版)[C].北京:中国科学技术出版社,2002.47—53.
  • 5International Agency for Research on Cancer,World Health Organization.Schistosomes,liver flukes and Helicobacter pylori.1ARC Working Group on the Evaluation of Carcinogenic Risks to Humans,1994.IARC Monogr Eval Carcinog Risks Hum,1994,61:1-241.
  • 6Parsonnet J,Hansen S,Rodriguez L,et al.Helicobacter pylori infection and gastric lyphoma.N Engl J Med,1994,330:1267-1270.
  • 7ParsonnerJ.The incidence of Helicobacter pylori inefectioa.Aliment Pharmacol Ther,1995,9(suppl 2):45-51.
  • 8Drumm B,Perez-perez GI,Blaser MJ,et al.Intrafamilar culstering of Helicobacter pylori infection.N Engl Med..1990,322:359-363.
  • 9Gotoh A, Akamatsu T, Shimizu T, et al. Additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori. Helicobacter,2002,7 : 183-191.
  • 10Gurbuz AK, Ozel AM, Ozturk R, et al. Effect of N-acetyl cysteine on Helicobacter pylori. South Med J, 2005,98: 1095- 1097.

共引文献975

同被引文献32

引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部